Gerdle B, Leinhard OD, Lund E, Lundberg P, Forsgren MF, Ghafouri B, (2024), Pain and the biochemistry of fibromyalgia: patterns of peripheral cytokines and chemokines contribute to the differentiation between fibromyalgia and controls and are associated with pain, fat infiltration and content, Frontiers in Pain Research, https://doi.org/10.3389/fpain.2024.1288024
A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol
Nasr P, Forsgren M, Balkhed W, Jönsson C, Dahlström N, Simonsson C, Cai S, Cederborg A, Henriksson M, Stjernman H, Rejler M, Sjögren D, Cedersund G, Bartholomä W, Rydén I, Lundberg P, Kechagias S, Leinhard OD, Ekstedt M, (2023) A rapid, non-invasive, clinical surveillance for CachExia, sarcopenia, portal hypertension, and hepatocellular carcinoma in end-stage liver disease: the ACCESS-ESLD study protocol, BMC Gastroenterology, https://doi.org/10.1186/s12876-023-03093-8
Skewness in body fat distribution pattern links to specific cardiometabolic disease risk profiles
Linge J, Cariou B, Neeland IJ, Petersson M, Rodríguez Á, Leinhard OD, (2023), Skewness in body fat distribution pattern links to specific cardiometabolic disease risk profiles, JCEM, https://doi.org/10.1210/clinem/dgad570
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Sanyal.J A, Kaplan M Lee, Frias P J, Brouwers B, Wu O, Thomas K M, Harris C, Schloot C N, Du Y, Mather J K, Haupt A, Hartman L M, (2024) Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial, Nature Medicine, https://doi.org/10.1038/s41591-024-03018-2
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Tawil R, Wagner R K, Hamel I J, Leung G D, Statland M J, Wang H L, Genge A, Sacconi S, Lochmüller H, Reyes-Leiva D, Diaz-Manera J, Alonso-Perez J, Muelas N, Vilchez J J, Pestronk A, Gibson S, Goyal A N, Hayward J L, Johnson N, LoRusso S, Freimer M, Shieh B P, Subramony H S, van Engelen B, Kools J, Leinhard D O, Widholm P, Morabito C, Moxham M C, Cadavid D, Mellion L M, Odueyungbo A, Tracewell G W, Accorsi A, Ronco L, Gould J R, Shoskes J, Rojas L A, Jiang G J, (2024) Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial, The Lancet Neurology, https://doi.org/10.1016/S1474-4422(24)00073-5
Dissecting unique and common variance across body and brain health indicators using age prediction
Beck D, de Lange G A-M, Gurholt P T, Voldsbekk I, Maximov I I, Subramaniapillai S, Schindler L, Hindley G, Leonardsen H E, Rahman Z, van der Meer D, Korbmacher M, Linge J, Leinhard D O, Kalleberg T K, Engvig A, Sønderby I, Andreassen A O, Westlye T L, (2024) Dissecting unique and common variance across body and brain health indicators using age prediction, Human Brain Mapping, https://doi.org/10.1002/hbm.26685